MedTrace Logo

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

NCT03573518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2022-04-18

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BTX 1503

BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation

DRUG

Vehicle

Placebo

Sponsors & Collaborators

  • Botanix Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Anthony Robinson, CRNP · Head of Development, Botanix Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-26
Primary Completion
2019-08-16
Completion
2019-09-05
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03573518 on ClinicalTrials.gov